Company: BGLC
Filing Date: 2025-03-05
Form Type: 8-K
Source: 0001477932-25-001484
Chunk: 0

Company: BioNexus Gene Lab Corp
Filing Date: 2025-03-05
Form: 8-K
Item: Item 8.01
Chunk 0
---
Item 8.01 Other Events

On March 5, 2025, BioNexus Gene Lab Corp. (the “ Company”) issued a press release announcing that its Board of Directors has formally approved a new treasury strategy focused exclusively on Ethereum (ETH) as a strategic treasury asset. This decision positions the Company as a leader among Nasdaq-listed companies in prioritizing Ethereum for treasury management. The press release further states that this strategy aligns with recent announcements regarding Ethereum’s inclusion in the proposed U. S. Crypto Strategic Reserve.

In connection with this announcement, the Company has released an Ethereum Strategy Whitepaper, which provides detailed insight into the rationale for adopting Ethereum as a treasury asset. The whitepaper is publicly available on the Company’s website at www. bionexusgenelab. com/ethstrategy.

A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference. The information in this Item 8.01, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “ Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filing.

Item 9.01 Financial Statement and Exhibits.